gastrointestinal stromal tumours (GIST)

article

M&A outlook for pharma in 2025

23 January 2025 | By Catherine Eckford (European Pharmaceutical Review)

For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.

news

GSK acquisition to advance potential best-in-class GI tumour treatment

13 January 2025 | By Catherine Eckford (European Pharmaceutical Review)

The new acquisition by GSK could enable major advancement in the standard of care for gastrointestinal stromal tumours (GIST) after nearly two decades.

news

EMA’s human medicines committee (CHMP) September meeting highlights

20 September 2021 | By Anna Begley (European Pharmaceutical Review)

In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.

news

EMA’s human medicine committee (CHMP) meeting highlights, July 2021

26 July 2021 | By Anna Begley (European Pharmaceutical Review)

The Committee for Medicinal Products for Human Use (CHMP) recommended two medicines for approval and provided a negative opinion on Nouryant.

news

FDA approves Ayvakit, the first targeted gastrointestinal stromal tumour treatment

10 January 2020 | By Hannah Balfour (European Pharmaceutical Review)

The FDA has approved Ayvakit for the treatment of GISTs with platelet-derived growth factor receptor alpha mutations, following 84 percent response rate in clinical trials.